Environmental Engineering Reference
In-Depth Information
Table 9.2 Liposomal formulations approved for commercial applications and in clinical trials
Route of
entry
Status/clinical trial
phase
Trade name with major usage
Chemical name
Formulations
Company
Doxil/Caelyx (Breast and ovar-
ian neoplasm, multiple mye-
loma, hepatocellular carcinoma)
Doxorubicin
Stealth liposomes (Block
copolymeric micelles);
MPEG, HSPC, Chol, DPPC,
MSPC, and DSPE-PEG
2000
Suspension
(Intravenous)
Ortho Biotech; Schring-
Plough; Sequus, Menlo Park,
CA, USA
On the market since
1995 (USA) and
1996 (Europe);
Phase III
MiKasome (Complicated Uri-
nary Tract Infections, acute
infections in cystic fibrosis,
nosocomial pneumonia)
Amikacin
Liposome injection
Intravenous
Liposome Co., Princeton, NJ,
USA
Phase I
Arikace (Lung infection)
Amikacin
Liposome; DPPC, and chol
Inhaled as
aerosol
Phase III
SP1-077, Lipoplatin (Antican-
cer, mesothelioma)
Cisplatin
(cisPT) and its
analog
Stealth liposomes; HSPC,
cholesterol and DSPE-mPEG,
SPC, DPPG, chol, and DSPE-
mPEG
Intravenous
NeXstar, Boulder, CO, USA
Phase I/II and III
Stimuvax (Non-small-cell lung
carcinoma)
BLP25
lipopeptide
Monophosphoryl lipid A, chol,
DMPG, and DPPC
Subcutaneous
Phase III
Ambisome (Fungal infections)
Amphotericin
B (AmpB)
Liposomes (PC/Chol/DSPG/
HSPC)
Suspension
(i.v.)
Gilead Sciences; NeXstar,
Boulder, CO, USA
In the market since
1990 (Europe) and
1997 (USA)
DC99 (Breast and ovarian neo-
plasm, multiple myeloma)
Doxorubicin
Liposomes (Block copoly-
meric micelles); DPPC, MSPC
and DSPE-PEG
2000
Suspension
(i.v.)
Liposome Co., Princeton, NJ,
USA
Phase III
DaunoXome (Kaposi
s
Dunorubicin
Liposomes (emulsion) DSPC
and Chol
Suspension
(i.v.)
Gilead Sciences; NeXstar,
Boulder, CO, USA
On the market since
1996 (USA and
Europe)
'
sarcoma)
CPX-351 (Acute myeloid leu-
kemia II)
Cytarabine and
daunorubicin
Liposomes; DSPC, DSPG and
chol
Intravenous
Phase II
